Roivant Sciences Ltd. ROIV
Set alert
As of Nov 2, 10:54 AM ET
- YTD
- +66.96%
- 1 year
- +81.24%
- Open
- 36.95
- Prev close
- 36.91
- Mkt cap
- 26.17B
- Vol
- 1.10M
- Avg vol
- 7.63M
- EPS
- -0.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 36.23
- High
- 37.29
- Forward P/E
- -21.49
- Beta
- 1.10
- Short ratio
- 5.65
- Inst. own
- 78.64%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 36.64
- 200-d avg
- 31.44
- 1y target
- 50.00
5D chart
Events in this range
- Oct 28, 2026Rating: Citigroup · Buy → Buy
Signals (124)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 5 days ago |
| RSI: Overbought | Oct 28, 11:15 AM | 5 days ago |
| RSI: Overbought | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 6 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 6 days ago |
| RSI: Oversold | Oct 26, 3:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 1 week ago |
| SMA: Bullish | Oct 26, 10:55 AM | 1 week ago |
News
-
4 days ago benzinga.com
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.
4 days ago benzinga.com
If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 26.86% on an annualized basis producing an average annual return of 37.68%. Currently, Roivant Sciences has a…
1 week ago benzinga.com
Why Is Roivant Sciences Stock Surging Wednesday?
Roivant (ROIV) shares jump as Phase 3 CLARITY trials show brepocitinib effectively treats noninfectious uveitis & reduces steroid reliance.
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
2 weeks ago benzinga.com
Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 30.08% on an annualized basis producing an average annual return of 41.86%. Currently, Roivant Sciences has a…
3 weeks ago benzinga.com
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.
4 weeks ago benzinga.com
Transcript: Roivant Sciences Q1 2027 Earnings Conference Call
On Thursday, Roivant Sciences (NASDAQ:ROIV) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
1 month ago benzinga.com
Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a…
1 month ago benzinga.com
Immunovant Ends Autoimmune Skin Disorder Program
Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.
-
1 month ago benzinga.com
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus…
1 month ago benzinga.com
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
-
1 month ago benzinga.com
Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51
Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.
-
1 month ago benzinga.com
TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55
TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $50 to $55.
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $46
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $47
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $41 to $47.
1 month ago benzinga.com
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
-
1 month ago benzinga.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
-
1 month ago benzinga.com
Jefferies Maintains Buy on Roivant Sciences, Raises Price Target to $52
Jefferies analyst Dennis Ding maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $52.
1 month ago benzinga.com
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
1 month ago benzinga.com
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Roivant announced positive Phase 2 trial results for mosliciguat, demonstrating improved walk distance and reduced cardiac strain in PH-ILD.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…
-
1 month ago benzinga.com
Roivant Announces Results From Its Phase 2 PHocus Clinical Trial Evaluating Mosliciguat For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease; PHocus Met Its Primary Endpoint, Demonstrating Clinically Meaningful And Statistically Significant Placebo-Adjusted Reduction In Pulmonary Vascular Resistance
"PH-ILD remains one of the most challenging forms of pulmonary hypertension to treat, given the heterogeneity of the disease and the fact that existing therapies are approved in limited geographies…
2 months ago benzinga.com
FDA Clears First Targeted Dermatomyositis Treatment From Roivant
FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy that reduces steroid dependency.
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.
2 months ago benzinga.com
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
2 months ago benzinga.com
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
2 months ago benzinga.com
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $36 to $42.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $34 to $41.
-
2 months ago benzinga.com
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of…
4 months ago benzinga.com
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.
-
5 months ago benzinga.com
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $36
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $30 to $36.
-
5 months ago benzinga.com
TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $41
TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $38 to $41.
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $34 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $34 price target.
5 months ago benzinga.com
S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today
U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation fears ahead of Nvidia's results after the close.
5 months ago benzinga.com
Crude Oil Down 5%; Lowe's Posts Upbeat Earnings
US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe's Companies reported upbeat earnings.
5 months ago benzinga.com
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
-
5 months ago benzinga.com
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript
6 months ago benzinga.com
Europe Clears First Flu/COVID Combo Shot From Moderna
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.
8 months ago benzinga.com
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor concerns and clearing legal uncertainty.
-
8 months ago benzinga.com
Roivant Sciences' Subsidiary, Arbutus Biopharma Sign $2.25B Settlement With Moderna To Resolve All U.S., Global Enforcement Actions; Moderna To Pay $950M Upfront Payment To Genevant, Arbutus
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (NASDAQ:ROIV),…
8 months ago benzinga.com
Caterpillar To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Caterpillar To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
8 months ago benzinga.com
Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?
Last week's top large-cap gainers surged on strong earnings beats and upbeat guidance (LITE, XPO, RRX, WWD, TPR), analyst upgrades (TER), oil-linked transport tailwinds (SAIA), and major catalysts…
8 months ago benzinga.com
Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday?
The software-driven sell-off paused for a breather on Friday after eight straight sessions that had hammered the iShares Tech-Expanded Software Sector ETF (NYSE:IGV)
8 months ago benzinga.com
Nasdaq Jumps Over 400 Points; AutoNation Shares Surge Following Q4 Earnings
Nasdaq Jumps Over 400 Points; AutoNation Shares Surge Following Q4 Earnings
8 months ago benzinga.com
Strategy Posts Upbeat Q4 Results, Joins SunOpta, BILL Holdings, Mitek Systems And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining more than 700 points on Friday.
-
8 months ago benzinga.com
Earnings Scheduled For February 6, 2026
Earnings Scheduled For February 6, 2026
9 months ago benzinga.com
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
Sun Pharma is evaluating a potential $10 billion acquisition of Organon, a move that could become India's largest cross-border pharma deal.